EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study

Hedwig van Hove iD, Joyce E M van der Heijden, Anne van Uden, Violette M G J Gijsen, Rick Greupink, Saskia N de Wildt, Joris van Drongelen

Prenatal Diagnosis · 2026-04 · 46 (4) · 533-540

DOI: 10.1002/pd.70104 ↗

At a glance

Journal article in Prenatal Diagnosis, published online on 2026-02-27. Written by Hedwig van Hove and 6 co-authors. Institution: Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. Major MEDLINE topics: Sotalol, Models, Biological, Tachycardia, Anti-Arrhythmia Agents. Cited 1 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To establish an optimized sotalol dosing strategy for fetal tachycardia using a pregnancy physiologically based pharmacokinetic (PBPK) model.

Method

A verified PBPK model was developed incorporating pregnancy‐induced physiological changes and placental transfer. Simulations were performed to evaluate current dosing recommendations and alternative dosing scenarios were explored. To avoid maternal dose‐related toxicity (QT‐prolongation), we aimed for maternal concentrations < 2.5 mg/L. Based on neonatal concentration‐effect data, we aimed for fetal C trough concentrations of 0.4–1.0 mg/L.

Results

Model predictions for maternal and fetal plasma concentrations were generally consistent with available maternal and fetal exposure data. Simulations showed that at the maximum oral daily dose of 480 mg, 16% of maternal concentrations exceeded the toxicity threshold, while 90% of fetuses had therapeutic C trough levels. Reducing the daily dose to 400 mg lowered maternal overexposure to 0.1%, with 87% of fetuses still reaching therapeutic levels. Additionally, splitting the 480 mg dose into three administrations per day reduced maternal overexposure to 0.3% and increased fetal target attainment to 95%.

Conclusion

Pregnancy PBPK modeling is a valuable tool for optimizing fetal sotalol therapy. A daily dose not exceeding 400 mg, or dividing daily doses of 240 mg and higher into three administrations, may optimize the balance between predicted fetal efficacy and maternal toxicity risk.

Subjects

MeSH terms (MEDLINE)

SotalolModels, BiologicalTachycardiaAnti-Arrhythmia AgentsFetal DiseasesHumansFemalePregnancyDose-Response Relationship, DrugMaternal-Fetal Exchange

Substances

SotalolAnti-Arrhythmia Agents

Authors and institutions

  • Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Neonatal and Pediatric Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
  • Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID profiles: Hedwig van Hove

Funding

  • Gates Foundation
  • Bill and Melinda Gates Foundation

Cite

APA

van Hove, H., van der Heijden, J. E. M., van Uden, A., Gijsen, V. M. G. J., Greupink, R., de Wildt, S. N., & van Drongelen, J. (2026). Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis, 46(4), 533-540. https://doi.org/10.1002/pd.70104

Vancouver

van Hove H, van der Heijden JEM, van Uden A, Gijsen VMGJ, Greupink R, de Wildt SN, et al. Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis. 2026;46(4):533-540. doi:10.1002/pd.70104

BibTeX
@article{vanHove2026,
  author = {van Hove, Hedwig and van der Heijden, Joyce E M and van Uden, Anne and Gijsen, Violette M G J and Greupink, Rick and de Wildt, Saskia N and van Drongelen, Joris},
  title = {Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study},
  journal = {Prenatal Diagnosis},
  year = {2026},
  volume = {46},
  number = {4},
  pages = {533--540},
  doi = {10.1002/pd.70104}
}
Start for free →